Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase III Study of Subcutaneous Secukinumab in Japanese Patients With Active Ankylosing Spondylitis
jRCT2080223186Phase 3
- Sponsor
- Novartis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of secukinumab in ankylosing spondylitis (AS), sponsored by Novartis.
02
Drugs
secukinumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on jRCT2080223186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223186.